Search 

Ischemia Care (ISC) is a clinical stage, capital efficient, venture capital backed, diagnostic laboratory company commercializing ISCDX, a blood test for cause of ischemic stroke (including atrial fibrillation or “AF”), leading to timely diagnosis and treatment, resulting in hospital cost savings and improved patient outcomes. ISC is executing on the Biomarkers of Acute Stroke Etiology (BASE) study , clinicaltrials.gov identifier NCT02014896 to support clinical adoption as an LDT through a company owned CLIA laboratory. ISC's initial focus is on the 40% (320K annually) ischemic strokes which are diagnosed as unkown cause (or "cryptogenic") as these patients typically are undertreaked and at a high risk for recurrence.

Stroke is the third leading cause of death worldwide with 20M annual events. In the US, there are 800K strokes, of which 195K are recurrent. Despite advances in imaging, cardiac monitoring, patient history assessment, and clinical examination, in 40% of ischemic strokes, the cause is unknown (or “cryptogenic”) leading to high recurrence and death.  There are no blood tests for cause of stroke. The identification of cause will change outcomes per Stroke Guidelines by adoption of “cause based” treatment regimen to prevent a more massive, debilitating, and costly recurrence. For example, identifying “undetected” AF in cryptogenic patients provides a 60% risk recurrence reduction.

Joslin Diabetes Center is a foundation based in Boston, Massachusetts that was founded in 1898, and is the world's largest diabetes and clinical care organization.

Jump Capital was founded in 2012 and is based in Chicago, with an additional office in San Francisco. The firm is investing from a $250m fund, and is interested in a variety of sectors including the life science field. For life science investments, Jump Capital typically allocates $2-15 million, and prefers to invest in Series B-C rounds. Jump Capital invests in the USA and Canada, and has previously invested in 6 healthcare companies.

Jump Capital invests in medical devices, diagnostics, digital and mobile health, and healthcare services. The firm is open to opportunities in any clinical indication. Jump Capital is only interested in devices and diagnostics that have in-human data.

Life Science Angels Inc was founded in 2004 and is based in Sunnyvale CA. The group makes early-stage equity investments in a wide range of life science companies. Life Science Angels invests primarily in California but is open to investing out of state provided a round is being syndicated with a local angel group. Life Science Angels does not rule out investing outside the USA but has yet to do so. The group invests as individuals and allocation sizes are therefore highly varied but are usually of about $2-$6, Life Science Angels usually invests in rounds seeking $3 million or less. The group is interested in syndicating rounds with other angel groups.

Life Science Nation (LSN) is the premier sourcing platform for market intelligence and prospect pipeline development in the life science arena. LSN enables life science professionals to generate a list of qualified global targets that are a fit for their company’s products, services, and fundraising efforts. The ability to generate these Global Target Lists (GTLs) makes life science professionals more effective and efficient. 

Lilly Asia Ventures is the venture capital arm of Eli Lilly that focuses on investments in the life sciences in Asia, particularly China. The firm was established in 2008 and is based in Shanghai, China. The firm is stage agnostic; investing in early, growth, and up to pre-IPO opportunities. The firm’s investment size is USD 5-20 million per company. The firm primarily invests in companies in China, but is open to companies across Asia-Pacific as long as there is some sort of China angle. The firm is actively seeking new investment opportunities.

Lilly Asia Ventures primarily focuses on therapeutics but is also interested in medical devices, diagnostics, animal health, and biotech other. The firm is most interested in products that will have a significant impact on medical care in China. For therapeutics, the firm seeks best-in-class or first-in-class products. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA. Historically, the firm invests in therapeutics for oncology, inflammatory diseases, and metabolic disorders.

Longitude Capital is a private equity group founded in 2006 with offices in Menlo Park, California and Greenwich, Connecticut. The firm has $700 million in assets and has raised two funds, with the most recent fund closing at $385m in 2012. Longitude makes both venture-stage and growth-stage equity investments, which are typically in the $10-30 million range. Longitude Capital primarily invests in North America and the European Union but may also consider opportunities in the Middle East.

Lumira Capital is a Venture Capital firm that changed its name from MDS Capital In 2007 and have been investing in companies since 1989. The firm is based in Toronto will additional offices in Boston and Montreal. The firm currently manages 2 funds for a total of approximately $180 million in assets under management. The firm’s Lumira Capital II fund currently hold approximately $115 million in assets and is looking to invest in companies across North America. The firms Merck Lumira Biosciences fund formed via a partnership with Merck Serano, currently holds around $65 million in assets and is looking for early stage opportunities in companies located in or looking to move to Quebec. The firm typically makes initial investments ranging from $2-$5 million of equity and looks to invest $8-$12 million over the lifetime of the investment. The firm plans to make 4-6 investments over the next 6-9 months.